SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the first quarter ended March 31, 2009. Revenues for the quarter ended March 31, 2009 were $25.3 million, compared to $27.9 million for the comparable period in 2008. The decrease from 2008 to 2009 primarily reflects the decrease in revenue due to the conclusion of various collaboration agreements partially offset by revenues associated with the license fee payments under the new cancer collaboration with Bristol-Myers Squibb Company for XL184 and XL281.
